After grabbing 1.79 million shares, the institutional investor is now in possession of 1.79 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.40% having worth around $6.71 million. Moreover, Point72 Asset Management LP increased its share by 0.96 million to have a control over 0.96 million shares. And Deerfield Management Co. LP raised its holdings to 0.87 million shares by acquiring 0.87 million shares or 5.06% of the stake.
Abeona Therapeutics Inc. (ABEO) concluded trading on 01/11/23 at a closing price of $2.73, with 1.6 million shares of worth about $4.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.94% during that period and on Wednesday the price saw a loss of about -10.49%. Currently the company’s common shares owned by public are about 17.18M shares, out of which, 15.35M shares are available for trading.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 21 times over the past 12 months. They bought 635,769 shares in 16 of the transactions. In 5 selling transactions, insiders dumped 137,211 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and DFA US Targeted Value Portfolio are the top 3 mutual funds which are holding stakes in Abeona Therapeutics Inc. Vanguard Total Stock Market Index is currently holding 0.24 million shares of worth totaling $0.88 million. The company recently came buying 0.0 shares which brought its stake up to 1.37% of the company’s outstanding shares. DFA US Targeted Value Portfolio, after buying 21924.0 shares, have now control over 0.13% of the stake in the company. It holds 21924.0 shares of worth $82434.0.
However, the stock later moved at a day high price of 3.1400, or with a loss of -10.49%. Stock saw a price change of -10.78% in past 5 days and over the past one month there was a price change of -12.50%. Year-to-date (YTD), ABEO shares are showing a performance of -11.36% which decreased to -63.76% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.34 but also hit the highest price of $9.35 during that period. The average intraday trading volume for Abeona Therapeutics Inc. shares is 437.46K. The stock is currently trading -3.24% below its 20-day simple moving average (SMA20), while that difference is down -21.97% for SMA50 and it goes to -37.18% lower than SMA200.
Ecor1 Capital LLC acquired 1.79 million shares of Abeona Therapeutics Inc. having value of about $6.71 million. Abeona Therapeutics Inc. (NASDAQ: ABEO) currently have 17.18M outstanding shares and institutions hold larger chunk of about 7.10% of that. Holding of mutual funds in the company is about 29.49% while other institutional holders and individual stake holders have control over 3.24% and 2.45% of the stake respectively.
The stock has a current market capitalization of $46.57M and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$18.26 in the same period. It has Quick Ratio of 2.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABEO, volatility over the week remained 8.96% while standing at 10.28% over the month.
Analysts are in expectations that Abeona Therapeutics Inc. (ABEO) stock would likely to be making an EPS of -$1.47 in the current quarter, while forecast for next quarter EPS is -$1.19 and it is -$1.65 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.76 which is -$0.95 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.75 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 5.10% while it is estimated to decrease by -40.90% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on November 11, 2020 offering an Overweight rating for the stock and assigned a target price of $4 to it. Coverage by B. Riley FBR stated Abeona Therapeutics Inc. (ABEO) stock as a Buy in their note to investors on September 18, 2020, suggesting a price target of $5 for the stock. On February 10, 2020, SVB Leerink Initiated their recommendations, while on December 10, 2019, Cantor Fitzgerald Resumed their ratings for the stock with a price target of $4. Stock get a Hold rating from Maxim Group on August 15, 2019.
